Keyphrases
Cardia
100%
Without Diabetes
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Sotagliflozin
100%
Ejection Fraction
33%
Heart Failure
33%
Patients with Diabetes
33%
Cardiovascular Events
33%
Heart Failure Patients
33%
Non-diabetic
33%
Type 2 Diabetic Patients
33%
Diabetic Heart Failure
33%
Effective Therapy
16%
Quality of Life
16%
Cardiovascular Risk
16%
Cardiovascular Mortality
16%
Clinical Trials
16%
Placebo
16%
Hospitalization
16%
Cardiac Magnetic Resonance
16%
Left Ventricular Mass
16%
Patient's Will
16%
Prospective Randomized Trial
16%
Placebo-controlled Study
16%
Worsening Heart Failure
16%
Most Common Form
16%
Chronic Kidney
16%
Potential Gains
16%
Cardiovascular Outcomes
16%
6-minute Walk Test (6MWT)
16%
Renal Impairment
16%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
16%
Non-diabetic Population
16%
Myocardial Fibrosis
16%
VO2peak
16%
Myocardial Mechanics
16%
Epicardial Adipose Tissue
16%
Myocardial Volume
16%
Universal Definition
16%
SGLT1
16%
Renal Events
16%
Pharmacological Class
16%
Cardiorenal Benefits
16%
Definition of Heart Failure
16%
Morbimortality
16%
Medicine and Dentistry
Diabetes
100%
Heart Failure with Preserved Ejection Fraction
100%
Sotagliflozin
100%
Congestive Heart Failure
83%
Cardiovascular System
50%
Ejection Fraction
33%
Diabetes Mellitus
33%
Patient with Diabetes
33%
Patient with Type 2 Diabetes
33%
Quality of Life
16%
Adipose Tissue
16%
Clinical Trial
16%
Placebo
16%
Cardiovascular Risk
16%
Cardiac Magnetic Resonance Imaging
16%
Placebo-Controlled Study
16%
Cardiovascular Mortality
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Moderate Renal Impairment
16%
Cardiac Fibrosis
16%
Six Minute Walk Test
16%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Preserved Ejection Fraction
100%
Sotagliflozin
100%
Congestive Heart Failure
83%
Diabetes Mellitus
33%
Non Insulin Dependent Diabetes Mellitus
33%
Clinical Trial
16%
Syndrome
16%
Placebo
16%
Cardiovascular Risk
16%
Placebo-Controlled Study
16%
Cardiovascular Mortality
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Moderate Renal Impairment
16%
Heart Muscle Fibrosis
16%